MedTrace Logo

Avelumab With Radiotherapy in Patients With Leptomeningeal Disease

NCT03719768 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-03-02

No results posted yet for this study

Summary

This study is to find a safe dose of the combination of Avelumab and Whole Brain Radiotherapy (WBRT) in patients with Leptomeningeal Disease.

Conditions

  • Leptomeningeal Metastases
  • Leptomeningeal Disease

Interventions

DRUG

Avelumab

Patients will be given 800 mg Avelumab as a one hour intravenous infusion once every 2 weeks.

RADIATION

Whole Brain Radiotherapy

Patients will be given 3000 cGy Whole Brain Radiotherapy once every 2 weeks

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • H. Lee Moffitt Cancer Center and Research Institute

    lead OTHER

Principal Investigators

  • Peter A Forsyth, MD · H. Lee Moffitt Cancer Center and Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-10
Primary Completion
2022-07-19
Completion
2024-08-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03719768 on ClinicalTrials.gov